Exp 7: Direct & Indirect Immunofluorescence Assay (IFA): Detection of Antinuclear Antibodies (ANA) on HEp-2 Substrates

Immunofluorescence (IFA) was developed in 1941 by Albert Coons, who demonstrated that antibodies could be covalently conjugated to fluorescent dyes (fluorochromes) without impairing their antigen-binding specificity.

A fluorophore absorbs high-energy photons at a shorter excitation wavelength ($lambda_{text{ex}}$), promoting electrons to an excited singlet state. As electrons relax to the ground state, they release photons of lower energy and longer wavelength ($lambda_{text{em}}$)—a phenomenon termed Stokes Shift. The most common fluorophore in diagnostic immunology is Fluorescein Isothiocyanate (FITC), which absorbs blue light at $lambda_{text{ex}} = 495,text{nm}$ and emits intense apple-green fluorescence at $lambda_{text{em}} = 519,text{nm}$.

• Direct Immunofluorescence (DIF): A single-step assay where a fluorochrome is directly conjugated to the primary antibody that recognizes the tissue-bound antigen. Used primarily for detecting immunoglobulin and complement depositions in renal biopsies (glomerulonephritis) and skin biopsies (pemphigus vulgaris).
• Indirect Immunofluorescence (IIF): A two-step assay where unlabeled patient serum antibody binds to an immobilized substrate (e.g., HEp-2 cells). After washing away unbound serum, a secondary anti-human IgG antibody labeled with FITC is added. Because multiple secondary antibody molecules bind to the constant Fc domain of each primary antibody, IIF provides dramatic 5- to 10-fold signal amplification, making it the international gold standard for screening autoantibodies.